Akagera Medicines, Inc
Daryl Drummond is a highly experienced scientific leader currently serving as Chief Scientific Officer at Akagera Medicines, Inc. since July 2019. Previously, Daryl held the position of Interim Head of Research & Development at Tidal Therapeutics, a Sanofi Company, from October 2019 to December 2023, and served as a Senior Biotech Consultant specializing in nanotherapeutics development from June 2019 to August 2023. From June 2014 to July 2019, Daryl was the Head of Research and Senior Vice President at Merrimack. Daryl also held leadership roles at Merrimack Pharmaceuticals and Hermes Biosciences, focusing on drug discovery and liposome research. Daryl's academic credentials include a Ph.D. in Biochemistry and a second Ph.D. in Chemistry from Indiana University Bloomington, a Post Doctorate in Nanotechnology and Drug Delivery from California Pacific Medical Center, and an Executive Education program in Leadership and Strategy from Harvard Business School.
This person is not in any teams
Akagera Medicines, Inc
Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and Proof of Concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020. The moral purpose of Akagera Medicines is to create medicines that lead to a world free of tuberculosis (TB), humankind’s greatest killer. This means improving efficacy, shortening the duration of treatment, optimizing drug/drug interaction, eliminating toxicity, and lowering the costs to patients and to society. Our Goals • to initiate clinical trials in humans in 2022; • to reduce the global incidence of TB deaths by 80% in the next decade; • to eradicate the multi-drug resistant (MDR) form of TB; • to explore the high probability that Akagera Medicines' approach will work to create treatments and vaccines in other infectious diseases like MRSA, Malaria, and HIV; • and to ensure that those treatments could be created, tested, and manufactured in the heart of Africa.